It's nice to see the FDA smartening up and not dropping the ball like they did with T-DM1 (granted, the melanoma trial was much more extensive and in a different indication).
I would like to begin building a position in IMGN at these levels if I can free up some of the CRAP that I currently own. T-DM1 should already be approved IMO.
Market Data 
Markets 
AI
